Cerus Stock Price, News & Analysis

Welcome to our dedicated page for Cerus news (Ticker: CERS), a resource for investors and traders seeking the latest updates and insights on Cerus stock.

Cerus Corporation (NASDAQ: CERS) is a biomedical products company focused on blood transfusion safety through its INTERCEPT Blood System and related technologies. This news page aggregates company announcements, financial updates, clinical milestones, and partnership news that Cerus releases through channels such as Business Wire and SEC-furnished press releases.

Readers can find coverage of quarterly and annual financial results, where Cerus reports product revenue from INTERCEPT platelet, plasma, and INTERCEPT Fibrinogen Complex (IFC) sales, along with government contract revenue tied to research and development programs. These releases often include updated product revenue guidance ranges and commentary on commercial performance in various geographies.

The news flow also highlights clinical and regulatory developments, including progress of the INTERCEPT red blood cell system in late-stage clinical development, Phase 3 trials such as RedeS, and regulatory review activities in Europe and the United States. Updates on the INT200 LED-based illumination device and development of lyophilized IFC (LyoIFC), supported by U.S. Department of Defense funding, are also featured.

In addition, Cerus issues news about strategic collaborations and industry engagement, such as group purchasing agreements with organizations like Blood Centers of America and participation in professional meetings, workshops, and conferences in transfusion medicine. These items describe efforts to expand access to pathogen-protected blood components and to share data on INTERCEPT technologies.

Investors, clinicians, and other stakeholders can use this page to follow Cerus’ latest disclosures on product adoption, revenue trends, government-supported projects, and scientific presentations related to blood safety and pathogen reduction.